Benchmark Starts Chembio Diagnostics (CEMI) at Speculative Buy; Potential Over-the-Counter HIV Resting Market
Tweet
Share
E-mailGet Alerts CEMI Hot Sheet
Price: $0.46 --0%
Rating Summary:
1 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 12 | New: 19
Rating Summary:
1 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 9 | Down: 12 | New: 19
Join SI Premium – FREE
Benchmark initiates coverage on Chembio Diagnostics (OTC: CEMI) with a Speculative Buy. PT $1.75.
Analyst, Raymond Myers, said, "We believe the Company can leverage its DPP rapid diagnostic test platform to address attractive infectious disease testing markets, including HIV, HCV, syphilis, and others. Chembio is well positioned to be the second entrant to the potential over-the-counter HIV testing market. The first entrant, OraSure (Nasdaq: OSUR)(not covered) has a market capitalization of over $500 million that we believe is substantially supported by this estimated $150-$500 million OTC-HIV market opportunity. We believe Chembio is attractively priced with a $30 million enterprise value, which is 1.2x current year forecast revenue of $24.4 million."
For an analyst ratings summary and ratings history on Chembio Diagnostics click here. For more ratings news on Chembio Diagnostics click here.
Shares of Chembio Diagnostics closed at $0.48 yesterday.
Analyst, Raymond Myers, said, "We believe the Company can leverage its DPP rapid diagnostic test platform to address attractive infectious disease testing markets, including HIV, HCV, syphilis, and others. Chembio is well positioned to be the second entrant to the potential over-the-counter HIV testing market. The first entrant, OraSure (Nasdaq: OSUR)(not covered) has a market capitalization of over $500 million that we believe is substantially supported by this estimated $150-$500 million OTC-HIV market opportunity. We believe Chembio is attractively priced with a $30 million enterprise value, which is 1.2x current year forecast revenue of $24.4 million."
For an analyst ratings summary and ratings history on Chembio Diagnostics click here. For more ratings news on Chembio Diagnostics click here.
Shares of Chembio Diagnostics closed at $0.48 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Deutsche Bank Starts Ardagh Metal Packaging S.A. (AMBP) at Hold
- Jefferies Starts Turtlemint Fintech Solutions (TURTLEMI:IN) at Buy
- BTIG Starts Lifeway Foods (LWAY) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
